4-Chloro-7-((1-methylpiperidin-4-yl)methoxy)quinazoline | 1355965-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-Chloro-7-((1-methylpiperidin-4-yl)methoxy)quinazoline
• 英文别名: 4-chloro-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
• CAS: 1355965-34-2
• 化学式: C₁₅H₁₈ClN₃O
• 分子量: 291.78
• InChiKey: STEALCOENMNORQ-UHFFFAOYSA-N

物化性质

• 沸点：
  425.6±25.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-aminophenyl)-N′-(3-fluorophenyl)urea 、 4-Chloro-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 以 异丙醇 为溶剂， 反应 2.0h， 生成 Urea, N-(3-fluorophenyl)-N'-[4-[[7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl]amino]phenyl]-
  参考文献：
  名称：

  Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase

  摘要：

  We report herein the design and synthesis of novel 4-aminoquinazoline derivatives based on the inhibitors of VEGFR-2 tyrosine kinases. The VEGFR-2 inhibitory activities of these newly synthesized compounds were also evaluated and compared with that of ZD6474. We found that most of target compounds had good inhibitory potency. In particular, compounds 1h, 1n and 1o were found to be 6, 2 and 2-fold more potent than the positive control ZD6474. The leading compound 1h also showed an in vivo activity against HepG2 human tumor xenograft model in BALB/c-nu mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.061
• 作为产物：
  描述：

  1-甲基-4-哌啶甲醇 在 氯化亚砜 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-Chloro-7-((1-methylpiperidin-4-yl)methoxy)quinazoline
  参考文献：
  名称：

  Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase

  摘要：

  We report herein the design and synthesis of novel 4-aminoquinazoline derivatives based on the inhibitors of VEGFR-2 tyrosine kinases. The VEGFR-2 inhibitory activities of these newly synthesized compounds were also evaluated and compared with that of ZD6474. We found that most of target compounds had good inhibitory potency. In particular, compounds 1h, 1n and 1o were found to be 6, 2 and 2-fold more potent than the positive control ZD6474. The leading compound 1h also showed an in vivo activity against HepG2 human tumor xenograft model in BALB/c-nu mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.061

文献信息

• [EN] ARYLUREA COMPOUND, INTERMEDIATE AND USE THEREOF<br/>[FR] COMPOSÉ D'ARYLURÉE, INTERMÉDIAIRE ET SON UTILISATION
  申请人：SHANGHAI INST PHARM INDUSTRY

  公开号：WO2012089137A1

  公开（公告）日：2012-07-05

  本发明公开了一种如式I所示的芳基脲类化合物或其药学上可接受的盐、多晶型物、溶剂合物或立体异构体，以及其中间体和应用。本发明的芳基脲类化合物I具有蛋白激酶抑制活性，以及抗肿瘤和抗血管新生活性。